biotech · Attention-Deficit Hyperactivity Disorder (ADHD) · ABVC
ABVC BIOPHARMA
ABVC BIOPHARMA, INC.
ABVC BioPharma is a biotech organization headquartered in Fremont, USA. It trades on NYSE under ticker ABVC. Primary therapeutic focus areas include Attention-Deficit Hyperactivity Disorder (ADHD). NovaPharmaNews links 1
Fremont, USA HQ
2015 Founded
10 Employees
Public company Type
ABVC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Fremont, USA
- Founded
- 2015
- Employees
- 10
- Programs
- 1
- Drugs
- 1
- Patents
- 0
PDC-1421 Capsule
Phase 2 · small molecule · Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Capsule for Attention-Deficit Hyperactivity Disorder (ADHD) is a Phase 2 program (small_molecule) at ABVC BIOPHARMA, INC. with 1 ClinicalTrials.gov record(s).
Internal code BLI-1008-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ABVC BIOPHARMA, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Status
- completed
- Trials
- 1